FY2019 Earnings Estimate for Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Issued By Cantor Fitzgerald

Share on StockTwits

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) – Stock analysts at Cantor Fitzgerald issued their FY2019 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a research report issued to clients and investors on Thursday, October 17th. Cantor Fitzgerald analyst A. Young forecasts that the biotechnology company will post earnings of $0.67 per share for the year. Cantor Fitzgerald has a “Neutral” rating on the stock. Cantor Fitzgerald also issued estimates for Arrowhead Pharmaceuticals’ FY2020 earnings at ($0.05) EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Monday, August 5th. The biotechnology company reported $0.21 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.34 by ($0.13). Arrowhead Pharmaceuticals had a return on equity of 26.27% and a net margin of 33.28%. The firm had revenue of $42.70 million for the quarter, compared to analysts’ expectations of $59.05 million.

A number of other analysts have also weighed in on the stock. BidaskClub upgraded shares of Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, October 9th. Robert W. Baird started coverage on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 2nd. They set an “outperform” rating and a $39.00 target price on the stock. ValuEngine lowered shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. B. Riley upped their target price on shares of Arrowhead Pharmaceuticals from $32.00 to $46.00 and gave the stock a “buy” rating in a research note on Monday, August 19th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $54.00 target price (up from $50.00) on shares of Arrowhead Pharmaceuticals in a research note on Sunday. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Arrowhead Pharmaceuticals has a consensus rating of “Buy” and an average target price of $37.50.

ARWR stock opened at $35.95 on Monday. The company’s 50 day moving average price is $30.92 and its 200 day moving average price is $26.35. Arrowhead Pharmaceuticals has a fifty-two week low of $10.41 and a fifty-two week high of $38.75. The firm has a market capitalization of $3.47 billion, a price-to-earnings ratio of -55.31 and a beta of 1.48.

In related news, Director Michael S. Perry sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $28.90, for a total value of $2,890,000.00. Following the completion of the transaction, the director now directly owns 121,000 shares of the company’s stock, valued at $3,496,900. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Christopher Richard Anzalone sold 56,325 shares of the company’s stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $31.83, for a total value of $1,792,824.75. Following the completion of the transaction, the chief executive officer now directly owns 2,178,228 shares of the company’s stock, valued at $69,332,997.24. The disclosure for this sale can be found here. Insiders sold 312,220 shares of company stock valued at $9,235,464 over the last ninety days. 4.80% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in ARWR. Nisa Investment Advisors LLC boosted its holdings in Arrowhead Pharmaceuticals by 96.2% in the third quarter. Nisa Investment Advisors LLC now owns 1,020 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 500 shares in the last quarter. Sound Income Strategies LLC acquired a new position in Arrowhead Pharmaceuticals in the second quarter valued at approximately $34,000. Acadian Asset Management LLC acquired a new position in Arrowhead Pharmaceuticals in the second quarter valued at approximately $34,000. Mascoma Wealth Management LLC acquired a new position in Arrowhead Pharmaceuticals in the second quarter valued at approximately $46,000. Finally, Pearl River Capital LLC acquired a new position in Arrowhead Pharmaceuticals in the second quarter valued at approximately $111,000. 71.98% of the stock is owned by hedge funds and other institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.

Read More: Trading Strategy Examples and Plans

Earnings History and Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.